25 completed, 10 recruiting, 8 terminated, 6 unknown. 23 Phase 2, 15 Phase 1, 8 Phase 3, 2 Not applicable, 2 Phase 4.
Follow Bulbo-Spinal Atrophy, X-Linked: new trials by email Literature Review of Bulbo-Spinal Atrophy, X-Linked trials Research Report on Bulbo-Spinal Atrophy, X-Linked
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | ORIC Pharmaceuticals | 600 | 2026-08-03 | 2026-10-05 |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs AZD9750, AZD5305 - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 6 | 2026-01-27 | 2026-10-02 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-09-29 |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer BMS-986365, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | Celgene | 960 | 2025-03-13 | 2026-09-30 |
| Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy Mexiletine hydrochloride, Placebo - Spinal and Bulbar Muscular Atrophy | Phase 2 / Phase 3 | Recruiting | Masahisa Katsuno | 68 | 2025-02-28 | 2025-04-16 |
| International SBMA Project (KDA) SBMA, Spinal and Bulbar Muscular Atrophy (SBMA) | Active not recruiting | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 700 | 2024-07-29 | 2026-03-02 | |
| Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution Exosome Secretome - Motor Disorders | Phase 1 | Completed | The Foundation for Orthopaedics and Regenerative Medicine | 70 | 2024-07-14 | 2026-10-16 |
| A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy Clenbuterol, Placebo - Spinal and Bulbar Muscular Atrophy | Phase 2 | Recruiting | Gianni Soraru | 90 | 2024-04-13 | 2024-04-15 |
| Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer Abemaciclib, Bicalutamide - Triple Negative Breast Neoplasms | Phase 2 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 53 | 2024-04-08 | 2026-04-01 |
| A Study of NIDO-361 in Patients With SBMA NIDO-361, Placebo - Spinal and Bulbar Muscular Atrophy, Kennedy's Disease | Phase 2 | Completed | Nido Biosciences, Inc. | 54 | 2024-03-01 | 2026-03-03 |
| Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris topical minoxidil in Acne Vulgaris - Acne Vulgaris | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 26 | 2023-07-11 | 2023-11-03 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients AJ201, Placebo - Spinal and Bulbar Muscular Atrophy, Kennedy's Disease | Phase 1 / Phase 2 | Completed | AnnJi Pharmaceutical Co., Ltd. | 25 | 2023-02-28 | 2024-08-15 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 8 | 2023-02-22 | 2024-01-25 |
| Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam OAV101 - Spinal Muscular Atrophy | Phase 3 | Completed | Novartis Pharmaceuticals | 27 | 2023-01-12 | 2026-01-13 |
| Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials onasemnogene abeparvovec - Spinal Muscular Atrophy (SMA) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 20 | 2022-12-19 | 2026-07-09 |
| Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS) Muscle biopsy - Amyotrophic Lateral Sclerosis, Kennedy Disease | Not applicable | Unknown | Assistance Publique - Hôpitaux de Paris | 40 | 2022-12-12 | 2024-02-07 |
| The Effect of Androgen Receptor Polymorphism on Endometrial Cancer Endometrial sampling and Peripheral blood collection, FSFI Scale - Androgen Receptor Abnormal, Endometrial Disorder | Unknown | University of Nicosia | 150 | 2022-04-01 | 2021-12-15 | |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Terminated | Rahul Aggarwal | 2 | 2022-03-16 | 2025-05-15 |
| A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer AC176 - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Terminated | Accutar Biotechnology Inc | 28 | 2022-03-16 | 2025-02-13 |
| Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA) OAV101 - Muscular Atrophy, Spinal | Phase 4 | Completed | Novartis Pharmaceuticals | 16 | 2021-11-04 | 2024-10-09 |
Showing 20 of 57. Sign in to see all of them.
Prostatic Neoplasms (14) · Muscular Atrophy, Spinal (7) · Motor Neuron Disease (6) · Amyotrophic Lateral Sclerosis (4) · Breast Neoplasms (4) · Muscular Atrophy (4) · Muscular Diseases (4) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (3) · Adenocarcinoma (2) · Motor Activity (2) · Rare Diseases (2) · Salivary Gland Neoplasms (2) · 3-Methylglutaconic Aciduria, Type V (1)
Central Nervous System Diseases (57) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (57) · Genetic Diseases, Inborn (57) · Genetic Diseases, X-Linked (57) · Heredodegenerative Disorders, Nervous System (57) · Nervous System Diseases (57) · Neurodegenerative Diseases (57) · Spinal Cord Diseases (57) · Neuromuscular Diseases (56) · Motor Neuron Disease (51) · Muscular Atrophy, Spinal (50) · Neoplasms (23) · Neoplasms by Site (23) · Male Urogenital Diseases (16) · Urogenital Diseases (16)
bicalutamide (5) · enzalutamide (5) · Zolgensma (3) · darolutamide (3) · Docetaxel (2) · Goserelin (2) · Leuprolide (2) · Prednisolone (2) · abiraterone (2) · exemestane (2) · 5'-ACCaagtttcttcAGC-3' (1) · AZD3514 (1) · AZD5305 (1) · Adrenal Cortex Hormones (1) · Anastrozole (1)
Novartis Pharmaceuticals (6) · National Institute of Neurological Disorders and Stroke (NINDS) (4) · Accutar Biotechnology Inc (2) · Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · AnnJi Pharmaceutical Co., Ltd. (1) · Astellas Pharma Inc (1) · Celgene (1) · Chang Gung Memorial Hospital (1) · Copenhagen University Hospital, Rigshospitalet (1) · Corcept Therapeutics (1) · Duke University (1) · Enzon Pharmaceuticals, Inc. (1) · Erasmus Medical Center (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
United States (29) · Italy (12) · United Kingdom (9) · France (8) · Japan (8) · Australia (7) · China (7) · Denmark (6) · Belgium (5) · Canada (5) · Spain (5) · Taiwan (5) · Brazil (4) · Germany (4) · Netherlands (4)
Christopher Grunseich, M.D. (2) · Aby Buchbinder, MD (1) · Adonis Ioannides, MD,PhD. (1) · Alexander Sherman (1) · Anna Ferrari, MD (1) · Cheng-Lung Hsu, Profesor (1) · Chiara Marini-Bettolo, MD, PhD (1) · Daniel Danila, MD (1) · Daniel George, MD (1) · Dionysios Vaidakis, MD,PhD. (1) · Douglas McNeel, MD, PhD (1)
PMID 12641825, PMID 19846582, PMID 21216197, PMID 23599814, PMID 23628801, PMID 24876969, PMID 26253932, PMID 26316780, PMID 27459230, PMID 27920066, PMID 28041951, PMID 28640128, PMID 30337273, PMID 31434793, PMID 31446511, PMID 31712062, PMID 32166698, PMID 32878613, PMID 33639779, PMID 34333820, PMID 35110415, PMID 35397772, PMID 35741698, PMID 39804575, PMID 40455815, PMID 41278139, PMID 41360995, PMID 42031429, PMID 42546251, PMID 42863747
2017 (1), 2023 (1), 2025 (1)